Nuvalent, Inc. (NUVL)

NASDAQ: NUVL · Real-Time Price · USD
103.59
+1.16 (1.13%)
Oct 11, 2024, 4:00 PM EDT - Market closed
1.13%
Market Cap 7.31B
Revenue (ttm) n/a
Net Income (ttm) -173.59M
Shares Out 70.55M
EPS (ttm) -2.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 298,312
Open 102.36
Previous Close 102.43
Day's Range 101.76 - 104.72
52-Week Range 49.02 - 113.51
Beta 1.29
Analysts Strong Buy
Price Target 113.78 (+9.84%)
Earnings Date Nov 12, 2024

About NUVL

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Ph... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 29, 2021
Employees 92
Stock Exchange NASDAQ
Ticker Symbol NUVL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for NUVL stock is "Strong Buy." The 12-month stock price forecast is $113.78, which is an increase of 9.84% from the latest price.

Price Target
$113.78
(9.84% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Nuvalent's lead candidates, NVL-520 and NVL-655, show promising efficacy and safety in Phase 1/2 trials. Both drugs have received FDA Breakthrough Therapy and orphan drug designations, with pivotal Ph...

20 days ago - Seeking Alpha

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass. , Sept. 18, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas...

24 days ago - PRNewsWire

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Nuvalent, Inc. achieved positive data from the phase 1/2 ALKOVE-1 study, using NVL-655 for the treatment of patients with ALK-mutant NSCLC. Positive data achieved from phase 1/2 ARROS-1 study, using z...

26 days ago - Seeking Alpha

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass. , Sept. 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas...

26 days ago - PRNewsWire

Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity

Over the weekend, Nuvalent, Inc. NUVL highlighted the presentation of updated data from Phase 1 dose-escalation portions of the ongoing ARROS-1 Phase 1/2 trial of zidesamtinib and ALKOVE-1 Phase 1/2 t...

27 days ago - Benzinga

Cancer Biotech Nuvalent's Stock Jumps on Positive Data

Biotech Nuvalent unveiled updates on two experimental cancer medicines over the weekend. Analysts say each could be the best in their category.

27 days ago - Barrons

Nuvalent Announces Public Offering of Common Stock

CAMBRIDGE, Mass. , Sept. 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas...

27 days ago - PRNewsWire

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of...

4 weeks ago - PRNewsWire

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Publication provides comprehensive assessment of NVL-655's preclinical activity and includes preliminary clinical case studies CAMBRIDGE, Mass. , Sept. 13, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq:...

4 weeks ago - PRNewsWire

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Updated Phase 1 data from ALKOVE-1 and ARROS-1 clinical trials to be presented at the ESMO Congress 2024 Durable activity of NVL-655 and zidesamtinib in heavily pre-treated patient populations support...

4 weeks ago - PRNewsWire

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

CAMBRIDGE, Mass. , Aug. 29, 2024 /PRNewswire/ --  Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas...

6 weeks ago - PRNewsWire

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

Company plans to host a conference call in conjunction with oral presentations at ESMO on September 14, 2024, at 8:30 a.m. ET/2:30 p.m.

2 months ago - PRNewsWire

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

CAMBRIDGE, Mass., July 22, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

2 months ago - PRNewsWire

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024

CAMBRIDGE, Mass. , July 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...

3 months ago - PRNewsWire

Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer

CAMBRIDGE, Mass. , July 11, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...

3 months ago - PRNewsWire

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer. NVL-520 targets ROS1-positive cancer and addresses treatment resist...

3 months ago - Seeking Alpha

Nuvalent (NUVL) CEO On The Future Of Cancer Treatments

Nuvalent is a clinical stage biopharma company that develops treatments for cancer patients. CEO James Porter weighs in on the FDA breakthrough therapy designation for NVL-655.

4 months ago - Schwab Network

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Nuvalent's NVL-655 received FDA Breakthrough Therapy Designation for ALK+ NSCLC, showing potential as a vital therapy. Nuvalent's pipeline includes innovative kinase therapies for NSCLC, with NVL-655 ...

4 months ago - Seeking Alpha

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass. , May 29, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

4 months ago - PRNewsWire

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

CAMBRIDGE, Mass. , May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

5 months ago - PRNewsWire

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results

Updates from the ongoing Phase 1/2 ARROS-1 and ALKOVE-1 clinical trials expected at a medical meeting in the second half of 2024 Strong financial position with operating runway anticipated into 2027 C...

5 months ago - PRNewsWire

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile  Zidesamtinib shown to be ...

6 months ago - PRNewsWire

Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024

CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

7 months ago - PRNewsWire

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results

Well-capitalized with operating runway anticipated into 2027 CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewswire/ --  Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on crea...

8 months ago - PRNewsWire

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520

CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...

8 months ago - PRNewsWire